Form 8-K - Current report:
SEC Accession No. 0001628280-25-005018
Filing Date
2025-02-12
Accepted
2025-02-12 07:22:34
Documents
19
Period of Report
2025-02-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20250212.htm   iXBRL 8-K 27533
2 EX-99.1 a2025-2x10aaaaimeetingda.htm EX-99.1 15355
6 a2025-2x10aaaaimeetingda001.jpg GRAPHIC 222370
7 a2025-2x10aaaaimeetingda002.jpg GRAPHIC 185780
8 a2025-2x10aaaaimeetingda003.jpg GRAPHIC 282202
9 a2025-2x10aaaaimeetingda004.jpg GRAPHIC 304894
10 a2025-2x10aaaaimeetingda005.jpg GRAPHIC 92459
  Complete submission text file 0001628280-25-005018.txt   1670979

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20250212.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20250212_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20250212_pre.xml EX-101.PRE 12504
21 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20250212_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 25611957
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)